Geoffrey Guy, executive chairman of GW Pharmaceuticals, has sold almost £600,000 of shares in the cannabis-based medicine firm to co-founder Brian Whittle.
The purchase of 750,000 shares from Guy at 79p each cost Whittle, who retired as a director at GW last year, £592,500.
Whittle and Guy set up the company in 1998 and listed it on the London Stock Exchange in June 2001.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Guy also gifted, for nil consideration, a further 782,111 shares to Whittle and members of Whittle's family.
Despite transferring over 1.5m shares, or 1.3% of the business, Guy still owns a 15.2% stake.
GW posted a maiden annual profit last month. It made £4m on revenue up to £16.1m from £5.7m thanks to increased sales and milestone revenue from Almirall and Sativax
Top Director Buys
Value: £129,366
Value: £53,480
Value: £35,340
Value: £24,878
Value: £24,878
Value: £22,825
Value: £19,902
Value: £11,750
Value: £11,600
Value: £10,536
Top Director Sells
Value: £592,500
-
Trump wants to colonise Mars – will it happen?Donald Trump wants to plant the US flag on Mars. Could humans really live there?
-
Klarna postpones US IPO as Trump's tariffs rattle marketsBuy-now-pay-later lender Klarna has postponed its US initial public offering owing to the market turbulence. It is not alone, says Matthew Partridge
